COVID-19 Vaccines and Ivermectin with MedCram and Dr. Roger Seheult

FoundMyFitness
02:23:46 Report Issue
Loading transcript... Click for full transcript

Chapters & Sections (88)

0:00 COVID Vaccine Necessity for Young People chapter 4
0:00 COVID-19 Vaccine Necessity for Young People
2:12 COVID-19 Delta Variant Affects Younger Population
3:33 COVID-19 Hospitalization Rate Concerns
5:18 US Healthcare System Overwhelmed by Infections
6:45 Vaccine Safety and Side Effects Discussion chapter 2
6:45 Vaccine Safety and Side Effects Discussion
9:58 COVID-19 Variants and Long-Haul Syndrome
11:57 COVID-19 Long-Term Brain Damage Effects chapter 2
11:57 COVID-19 Long-Term Brain Damage Effects
14:59 COVID-19 Comorbidity and Stroke Risks
19:57 COVID-19 Vaccine Safety and Spike Protein chapter 4
19:57 COVID-19 Vaccine Safety and Spike Protein
22:06 Vaccine Design and Spike Protein Conformation
23:41 Comparing Spike Proteins in Vaccines and SARS-CoV-2
25:59 Spike Protein Safety and COVID-19 Vaccine Concerns
28:36 mRNA Vaccine Safety and Efficacy Explained chapter 2
28:36 mRNA Vaccine Safety and Mechanism Explained
30:40 mRNA Vaccine Safety and Distribution Concerns
33:33 Vaccine Safety and Spike Protein Concerns chapter 2
33:33 Vaccine Safety and Spike Protein Concerns
35:21 COVID-19 Vaccine Safety and Adverse Events
38:45 Vaccine Safety and Reporting Requirements chapter 3
38:45 Vaccine Safety and Adverse Event Reporting
41:02 Vaccine Safety Reporting System Analysis
42:32 COVID-19 Vaccine Reporting and Adverse Events
44:51 Vaccine Safety and Underreporting Concerns chapter 3
44:51 Vaccine Safety and Underreporting Concerns
46:28 Vaccine Safety and Reporting Patterns
48:17 Analyzing VAERS Data for Confounding Factors
51:20 COVID-19 Vaccine Safety Compared to COVID-19 chapter 3
51:20 COVID-19 Vaccine Safety Compared to COVID-19
52:37 Vaccine Safety and Reporting System Explained
54:21 Vaccine Safety and Conspiracy Theories
56:05 Risk vs Benefit in Medical Decisions chapter 2
56:05 Medical Decisions and Risk vs Benefit
57:46 Vaccine Risks and Benefits Discussion
1:01:16 Antibody-Dependent Enhancement Explained by Dr. Patrick chapter 3
1:01:16 Antibody-Dependent Enhancement Explained
1:03:33 RSV Vaccine Clinical Trial Failure
1:05:01 Benefits of Pre-Fusion Viral Protein Vaccines
1:06:30 Antibody-Dependent Enhancement Concerns with Vaccines chapter 2
1:06:30 Antibody-Dependent Enhancement Concerns in Vaccines
1:09:45 Pregnancy Outcomes in COVID-19 Vaccine Trials
1:11:48 COVID-19 Vaccine Safety in Pregnancy chapter 3
1:11:48 COVID-19 Vaccine Safety in Pregnancy
1:14:12 mRNA Vaccine Technology and DNA Alteration
1:15:58 mRNA cannot alter human DNA
1:17:33 mRNA vaccines do not change DNA chapter 2
1:17:33 mRNA Vaccines and DNA Changes Debunked
1:20:10 Swiss Cheese Model of Risk Management
1:22:08 Ivermectin's Effectiveness in Treating COVID-19 chapter 2
1:22:08 Ivermectin's Effectiveness in Treating COVID-19
1:24:04 Ivermectin's Effectiveness in COVID-19 Treatment
1:27:49 Evaluating Therapeutic Options for COVID-19 chapter 5
1:27:49 Evaluating Ivermectin as COVID-19 Therapeutic
1:31:59 Ivermectin Study Limitations and Meta-Analysis
1:33:33 Ivermectin's Effectiveness in Viral Clearance
1:35:11 Ivermectin's Efficacy and Safety Concerns
1:36:48 Risks of Ivermectin Use for COVID-19
1:38:36 Ivermectin Studies Lack FDA Required Evidence chapter 3
1:38:36 Ivermectin Studies Lack Randomized Controlled Trials
1:41:08 COVID-19 Vaccination and Lifestyle Optimization
1:42:58 Transmission of SARS-CoV-2 Virus Explained
1:45:11 Vaccine Efficacy Against Delta Variant chapter 2
1:45:11 Vaccine Efficacy Against COVID-19 Variants
1:48:18 Vaccine Efficacy in Preventing Transmission
1:50:21 Vaccine Effectiveness in Preventing Breakthrough Infections chapter 4
1:50:21 Vaccine Effectiveness in Preventing Breakthrough Infections
1:52:46 Vaccinated Individuals Shed Less Infectious Virus
1:54:16 Vaccinated People Not Causing Outbreaks
1:55:59 Vaccine Effect on SARS-CoV-2 Virus Evolution
1:58:04 Virus Evolution and Transmissibility Factors chapter 3
1:58:04 Virus Evolution and Transmission Dynamics
2:00:10 COVID-19 Transmission and Mutation Concerns
2:02:00 Vaccine Effectiveness and Viral Mutation
2:03:25 Virus Mutations and Vaccine Effectiveness chapter 2
2:03:25 Viral Variants and Vaccine Effectiveness
2:05:51 Vaccine Efficacy and Resistance to Viruses
2:08:27 Vaccine Development Process and Acceleration chapter 4
2:08:27 Vaccine Development Process and Acceleration
2:10:29 Government Support for Vaccine Development
2:12:04 US Infrastructure Mobilization for War and Vaccine
2:13:42 mRNA Vaccine Development and History
2:15:30 History of mRNA Technology in Clinical Trials chapter 3
2:15:30 History of mRNA Technology in Humans
2:17:59 mRNA Technology for Solid Tumors Treatment
2:19:39 Vaccine Effectiveness Against Delta Variant

Transcript

Loading transcript...